CD274 and bladder transitional cell carcinoma: For this analysis, we acquired a dataset of 348 patients with metastatic BLCA (31) treated with the anti-PD-L1 agent atezolizumab and analyzed using RNA-seq and WES of the tumor, and IHC for TILs (a complete overview of CSG characteristics in this cohort can be found in Supplementary Table S3).